In addition to larger-scale translational and clinical studies, future efforts should also focus on investigating novel combination strategies with agents that induce BRCAness or stimulate the cGAS/STING pathway, with the goal of broadening the population who could benefit from immunotherapeutic approaches in pancreatic cancer. The gene discussed is CGAS; the disease is familial pancreatic carcinoma.